1. Home
  2. IMNM vs AXGN Comparison

IMNM vs AXGN Comparison

Compare IMNM & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.07

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Axogen Inc.

AXGN

Axogen Inc.

HOLD

Current Price

$43.74

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
AXGN
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
IMNM
AXGN
Price
$18.07
$43.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
9
Target Price
$32.80
$42.33
AVG Volume (30 Days)
1.2M
864.5K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
$225,208,000.00
Revenue This Year
N/A
$20.57
Revenue Next Year
$1,127.34
$16.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.21
52 Week Low
$7.96
$9.22
52 Week High
$27.65
$45.83

Technical Indicators

Market Signals
Indicator
IMNM
AXGN
Relative Strength Index (RSI) 33.00 60.55
Support Level $16.81 $29.48
Resistance Level $19.16 $44.83
Average True Range (ATR) 0.92 2.11
MACD -0.21 0.15
Stochastic Oscillator 1.24 85.42

Price Performance

Historical Comparison
IMNM
AXGN

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

Share on Social Networks: